Vaxart therapeutic HPV vaccine

Vaxart therapeutic HPV vaccine is an investigational **oral recombinant adenoviral therapeutic vaccine** being developed by **Vaxart** for **HPV-related cervical dysplasia**. The candidate uses Vaxart's proprietary mucosal **rAd5 oral pill vaccine platform** and is designed to express **HPV-16 and HPV-18 E6 and E7 oncoprotein antigens**, with the goal of inducing cellular immune responses, particularly **T-cell responses**, against HPV-expressing dysplastic or malignant cells. Unlike prophylactic HPV vaccines, it is intended as a **therapeutic** immunotherapy to treat established HPV-associated disease and potentially prevent progression toward cervical cancer. Based on the provided information, the program is in **preclinical development** and emphasizes room-temperature stability and needle-free oral administration.

Other names

Vaxart therapeutic HPV vaccineoral therapeutic HPV vaccineVaxart HPV vaccine